Oncomatryx Biopharma Revenue

Pharmaceutical Manufacturing • Derio, Basque Country, Spain • 21-50 Employees

Oncomatryx Biopharma revenue & valuation

Annual revenue	$2,566,650
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$8,300,000
Total funding	$45,400,000

Key Contacts at Oncomatryx Biopharma

Eneko Aldaba Arévalo

Director Of Manufacturing

Yosu Vara

Chemistry Director

Cristina Ferrer

Preclinical Development Director

Company overview

Headquarters	Science and Technology Park of Bizkaia Building 801B, Derio, Bizkaia 48160, ES
Phone number	+34946087037
Website	oncomatryx.com
NAICS	3254
SIC	873
Keywords	Oncology, Immunotherapy, Antibody Drug Conjugate (Adcs), Pancreatic Cancer, Precision Drugs, Stroma, Tumor Microenvironment
Founded	2009
Employees	21-50
Socials

Oncomatryx Biopharma Email Formats

Oncomatryx Biopharma uses 5 email formats. The most common is {first name}{last name} (e.g., johndoe@oncomatryx.com), used 61.9% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@oncomatryx.com	61.9%
{first initial}{last name}	jdoe@oncomatryx.com	19%
{first initial}{second initial}	jo@oncomatryx.com	9.5%
{first initial}{first3}	j{first3}@oncomatryx.com	4.8%
{first initial}	j@oncomatryx.com	4.8%

About Oncomatryx Biopharma

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

Director

Employees by Department

Oncomatryx Biopharma has 14 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore Oncomatryx Biopharma's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2022-05-19	1	$16,200,000
2025-02-27	1	$26,300,000
2025-08-14	9	$2,900,000

Funding Insights

$45,400,000

Total funding amount

$2,900,000

Most recent funding amount

Number of funding rounds

Oncomatryx Biopharma Tech Stack

Discover the technologies and tools that power Oncomatryx Biopharma's digital infrastructure, from frameworks to analytics platforms.

Autoptimize

Performance

reCAPTCHA

Security

Windows Server

Operating systems

ThemeGrill Spacious

WordPress themes

Google Maps

Maps

Microsoft 365

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

Google Analytics

Analytics

Frequently asked questions

Oncomatryx Biopharma is located in Derio, Basque Country, ES.

You can reach Oncomatryx Biopharma at +34946087037.

Oncomatryx Biopharma generates an estimated annual revenue of $2,566,650. This revenue figure reflects the company's market position and business performance in its industry.

Oncomatryx Biopharma has an estimated valuation of $8,300,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Oncomatryx Biopharma was founded in 2009, making it 17 years old. The company has established itself as a significant player in its industry over this time.

Oncomatryx Biopharma has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Oncomatryx Biopharma has raised a total of $45,400,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.